Research ArticleArticle
Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry
Paula S. Ramos, James C. Oates, Diane L. Kamen, Adrienne H. Williams, Patrick M. Gaffney, Jennifer A. Kelly, Kenneth M. Kaufman, Robert P. Kimberly, Timothy B. Niewold, Chaim O. Jacob, Betty P. Tsao, Graciela S. Alarcón, Elizabeth E. Brown, Jeffrey C. Edberg, Michelle A. Petri, Rosalind Ramsey-Goldman, John D. Reveille, Luis M. Vilá, Judith A. James, Joel M. Guthridge, Joan T. Merrill, Susan A. Boackle, Barry I. Freedman, R. Hal Scofield, Anne M. Stevens, Timothy J. Vyse, Lindsey A. Criswell, Kathy L. Moser, Marta E. Alarcón-Riquelme, Carl D. Langefeld, John B. Harley and Gary S. Gilkeson
The Journal of Rheumatology May 2013, jrheum.120989; DOI: https://doi.org/10.3899/jrheum.120989
Paula S. Ramos
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
James C. Oates
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Diane L. Kamen
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Adrienne H. Williams
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Patrick M. Gaffney
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Jennifer A. Kelly
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Kenneth M. Kaufman
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Robert P. Kimberly
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Timothy B. Niewold
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Chaim O. Jacob
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Betty P. Tsao
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Graciela S. Alarcón
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Elizabeth E. Brown
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Jeffrey C. Edberg
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Michelle A. Petri
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Rosalind Ramsey-Goldman
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
John D. Reveille
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Luis M. Vilá
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Judith A. James
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Joel M. Guthridge
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Joan T. Merrill
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Susan A. Boackle
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Barry I. Freedman
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
R. Hal Scofield
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Anne M. Stevens
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Timothy J. Vyse
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Lindsey A. Criswell
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Kathy L. Moser
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Marta E. Alarcón-Riquelme
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Carl D. Langefeld
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
John B. Harley
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Gary S. Gilkeson
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; Wake Forest School of Medicine and Center for Public Health Genomics, Winston-Salem, North Carolina, USA; Arthritis and Clinical Immunology Research Program, and Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA; Keck School of Medicine, University of Southern California, Los Angeles, California, USA; David Geffen School of Medicine, University of California, Los Angeles, California, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA; Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA; King’s College London, Divisions of Genetics and Molecular Medicine and Immunology, Infection and Inflammatory Disease, London, UK; Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California, USA; and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain. Supported by the South Carolina Clinical and Translational Research (SCTR) Institute, through US National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062; by NIH grant numbers R01 AR45476 (JCO), U54 RR026107 (JCO), R01 AI063274 (PMG), P01 AR49084 (RPK, CDL, JBH, EEB, JCE, JDR, RRG, MAP, LMV), R01 AR043274 (CDL, KLM), R01 AR33062 (RPK), R01 AR445650 (COJ), R01 AR043814 (BPT), P01 AR49084 (GSA), P30 AR055385 (EEB), 5UL1 RR025777 (JCE), AR43727 (MAP), K24 AR002138 (RRG), P60 2 AR30692 (RRG), UL 1 RR025741 (RRG), AI082714 (JAJ, JMG), AI101934 (JAJ), AR053843 (JAJ, JMG), AR058554 (JAJ, JMG), RR031152 (JAJ, JMG), R01 AR44804 (LAC), K24 AR02175 (LAC), P60 AR053308 (LAC), 5 M01 RR-00079 (LAC), RR020143 (KLM, MAR), AR042460 (JBH), AI024717 (JBH), AR062277 (JBH); and by the US Department of Veterans Affairs (JBH), the Mary Kirkland Scholarship (JBH, LAC), the Instituto de Salud Carlos III (PS09/00129 to MAR), FEDER funds of the European Union (MAR), the Lupus Foundation of Minnesota (KLM), arc project grant 17761 (TJV), Wellcome Trust programme grant 085492 (TJV), the Lupus Research Institute (BPT), Wake Forest School of Medicine Center for Public Health Genomics, and the Alliance for Lupus Research (COJ, LAC). P.S. Ramos, PhD; J.C. Oates, MD; D.L. Kamen, MD; G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina; A.H. Williams, MA; C.D. Langefeld, PhD, Wake Forest School of Medicine and Center for Public Health Genomics; P.M. Gaffney, MD; J.A. Kelly, MPH; J.M. Guthridge, PhD; K.L. Moser, PhD, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; K.M. Kaufman, PhD; J.B. Harley, MD, PhD, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center; R.P. Kimberly, MD; J.C. Edberg, PhD, Department of Medicine, University of Alabama at Birmingham; T.B. Niewold, MD, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago; C.O. Jacob, MD, PhD, Keck School of Medicine, University of Southern California at Los Angeles; B.P. Tsao, PhD, David Geffen School of Medicine, University of California Los Angeles; G.S. Alarcón, MD, MPH, Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama at Birmingham; E.E. Brown, PhD, MPH, Department of Epidemiology, University of Alabama at Birmingham; M.A. Petri, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine; R. Ramsey-Goldman, MD, DrPH, Division of Rheumatology, Northwestern University Feinberg School of Medicine; J.D. Reveille, MD, Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston; L.M. Vilá, MD, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus; J.A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center; J.T. Merrill, MD, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation; S.A. Boackle, MD, Division of Rheumatology, University of Colorado Denver; B.I. Freedman, MD, Department of Internal Medicine/Nephrology, Wake Forest School of Medicine; R.H. Scofield, MD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma Health Sciences Center, and US Department of Veterans Affairs Medical Center; A.M. Stevens, MD, PhD, Division of Rheumatology, Department of Pediatrics, University of Washington Seattle; T.J. Vyse, MA, MBBS, MRCP, PhD, King’s College London; L.A. Criswell, MD, MPH, DSc, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco; M.E. Alarcón-Riquelme, MD, PhD, Oklahoma Medical Research Foundation, and Centro de Genómica e Investigaciónes Oncológicas, Pfizer-Universidad de Granada-Junta de Andalucia. Address correspondence to Dr. P.S. Ramos, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA. E-mail: ramosp@musc.edu Accepted for publication February 14, 2013.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry
Paula S. Ramos, James C. Oates, Diane L. Kamen, Adrienne H. Williams, Patrick M. Gaffney, Jennifer A. Kelly, Kenneth M. Kaufman, Robert P. Kimberly, Timothy B. Niewold, Chaim O. Jacob, Betty P. Tsao, Graciela S. Alarcón, Elizabeth E. Brown, Jeffrey C. Edberg, Michelle A. Petri, Rosalind Ramsey-Goldman, John D. Reveille, Luis M. Vilá, Judith A. James, Joel M. Guthridge, Joan T. Merrill, Susan A. Boackle, Barry I. Freedman, R. Hal Scofield, Anne M. Stevens, Timothy J. Vyse, Lindsey A. Criswell, Kathy L. Moser, Marta E. Alarcón-Riquelme, Carl D. Langefeld, John B. Harley, Gary S. Gilkeson
The Journal of Rheumatology May 2013, jrheum.120989; DOI: 10.3899/jrheum.120989
Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry
Paula S. Ramos, James C. Oates, Diane L. Kamen, Adrienne H. Williams, Patrick M. Gaffney, Jennifer A. Kelly, Kenneth M. Kaufman, Robert P. Kimberly, Timothy B. Niewold, Chaim O. Jacob, Betty P. Tsao, Graciela S. Alarcón, Elizabeth E. Brown, Jeffrey C. Edberg, Michelle A. Petri, Rosalind Ramsey-Goldman, John D. Reveille, Luis M. Vilá, Judith A. James, Joel M. Guthridge, Joan T. Merrill, Susan A. Boackle, Barry I. Freedman, R. Hal Scofield, Anne M. Stevens, Timothy J. Vyse, Lindsey A. Criswell, Kathy L. Moser, Marta E. Alarcón-Riquelme, Carl D. Langefeld, John B. Harley, Gary S. Gilkeson
The Journal of Rheumatology May 2013, jrheum.120989; DOI: 10.3899/jrheum.120989